Mini-Gastric Bypass Whats in a Name? Mini gastric bypass (MGB) - - PowerPoint PPT Presentation

mini gastric bypass what s in a name
SMART_READER_LITE
LIVE PREVIEW

Mini-Gastric Bypass Whats in a Name? Mini gastric bypass (MGB) - - PowerPoint PPT Presentation

Mini-Gastric Bypass Whats in a Name? Mini gastric bypass (MGB) since 1997 Rutledge 2001 One-anastomosis gastric bypass (OAGB) Garcia-Caballero in 2004 Single-anastomosis gastric bypass (SAGB) Lee 2014 Omega loop


slide-1
SLIDE 1

Mini-Gastric Bypass

slide-2
SLIDE 2

What’s in a Name?

  • Mini gastric bypass (MGB) since 1997
  • Rutledge 2001
  • One-anastomosis gastric bypass (OAGB)
  • Garcia-Caballero in 2004
  • Single-anastomosis gastric bypass (SAGB)
  • Lee 2014
  • Omega loop gastric bypass (OLGB)
  • Himpens 2015
slide-3
SLIDE 3

One Anastomosis Gastric Bypass

  • Gastric pouch 15 ± 2.5 cm
  • Level of the crow’s foot
  • Gastrojejunostomy 200

(150-300) cm from ligament of Treitz

  • “Larger” G-J
  • 1.5 to > 3 cm
slide-4
SLIDE 4

Long Gastric Pouch

slide-5
SLIDE 5
slide-6
SLIDE 6
slide-7
SLIDE 7
slide-8
SLIDE 8

End-to-end vs Side-to-side

slide-9
SLIDE 9
slide-10
SLIDE 10
  • MGB 4th most common bariatric operation in

Europe and Asia

  • 5-10% of bariatric operations in many

countries

  • Annual volume up to 4000 operations per

year

slide-11
SLIDE 11

Bariatric Operations in 2013

Country Total AGB RYGB SG BPD/DS OAGB USA/Canada 154,276 15,523 54,420 67,021 1520 ?? France 37,300 7000 8000 18,000 300 4000 Italy 8106 2282 1733 2879 111 538 Egypt 5875 200 1300 2500 10 300 Austria 2354 115 1210 760 20 210 Turkey 3250 400 500 1500 115 200 Greece 1499 234 262 622 23 191 Spain 2425 28 1029 818 329 150 Poland 1658 209 318 913 140

slide-12
SLIDE 12

Controversies

  • Bile gastritis and esophagitis
  • Billroth II gastrectomy
  • Original Mason loop gastric bypass
  • No formal studies of bile reflux after

OAGB

  • ? Increased cancer risk
  • Bile and/or H. pylori
  • No published reports of such
slide-13
SLIDE 13
  • Bile reflux was most commonly seen complication (20 of

32 patients)

  • Diagnosis
  • Bilious vomiting or abdominal pain, bile gastritis on

endoscopy

  • Revision
  • Conversion to RYGB in 14
  • Braun enteroenterostomy in 2
  • Plans for conversion to RYGB in 4

Johnson, SOARD, 2007

slide-14
SLIDE 14
  • No bile reflux in 923 primary OAGB
  • Bile reflux in 5.19% of 77 revision OAGB
  • Treatment of bile reflux
  • Stapling afferent limb proximal to G-J and

creating Braun enteroenterostomy 70 cm distally

Noun, Obes Surg, 2012

slide-15
SLIDE 15

Potential Disadvantages

  • More malabsorption
  • More diarrhea
  • More marginal ulcers
  • More catastrophic gastrojejunostomy leak
slide-16
SLIDE 16

Potential Advantages

  • Emphasis on technical simplicity and shorter

OR times

  • ? Lower complication rate
  • Less internal hernia, bowel obstruction
  • Better weight loss
  • Greater resolution of co-morbidities
slide-17
SLIDE 17

The Data

slide-18
SLIDE 18
  • Mean follow-up 11.4 months
  • Pre-op BMI 48.1 kg/m2 (34.5 – 73.8)
  • OR time: 92.4 min (45 – 150)
  • Length of stay: 2.2 days (2 – 17)
  • Pouch with 36 French OG tube
  • Gastrojejunostomy 200cm from LOT
slide-19
SLIDE 19

Outcomes

  • No leaks
  • No mortality
  • Reoperation
  • 1 in first 30 days
  • Adhesion to terminal ileum (probably

unrelated)

  • 3 later
  • Perforated marginal ulcer (converted to RYGB)
  • Marginal ulcer (realignment of anastomosis)
  • Abdominal pain (adhesiolysis, crural closure)
slide-20
SLIDE 20

Complications

  • Wound infection (1)
  • Self-limited GI bleeding (1)
  • Marginal ulcer (4)
slide-21
SLIDE 21

Safety

  • Marginal ulcer comparable to RYGB
  • No internal hernias
  • GERD similar to

VSG

  • “No published proof of significant bile

gastroesophageal reflux after OAGB.”

  • ? More malabsorption than RYGB
  • “Unconvinced” of any increased risk of cancer
slide-22
SLIDE 22

Weight Loss

25 50 75 100 6 months 12 months 18 months 24 months 40.8 38.3 36.8 27.5 94.8 82.6 79.5 60.1 %EWL %TWL

(n=114) (n=65) (n=31) (n=6)

slide-23
SLIDE 23

Takeaways

  • Several 1000’s published cases world-wide
  • Still controversial
  • Held to higher level of scrutiny
  • Excellent patient satisfaction
  • Excellent weight loss
  • Excellent co-morbidity improvement
slide-24
SLIDE 24
  • 8 European centers
  • 313 patient with T2DM
  • MGB in 55.9%
  • VSG in 44.1%
  • Pouch 15 ± 2.5 cm long, GJ at 195 ± 25.5 cm
  • 1 year F/U in 63.7%
  • 85.7% of those eligible for 1 yr f/u
slide-25
SLIDE 25
slide-26
SLIDE 26

Safety

slide-27
SLIDE 27

Takeaways

  • OAGB has “very acceptable” risk
  • Similar to

VSG

  • Outperforms

VSG

  • Weight loss
  • T2DM remission
  • Reduction in BP
slide-28
SLIDE 28

Operation LSG (339) RYGB (295) OAGB (333) Mean BMI 35 42.5 56.5 Age 23 38 46.5 Female 45.4% 71.2% 70.4% T2DM 24.5 32.5 75.9 HTN 26.5 38.3 68.7 Dyslipidemia 23.3 36.3 60.7 Complete F/ U 97 (28.6%) 143 (48.5%) 167 (50.2)

  • Mean F/U of 53.5 (20-87) months
slide-29
SLIDE 29

Procedure LSG RYGB OAGB Number performed 339 295 473 Leaks 5 1 Mild hypoalbuminemia (2.5-3.5) 6 44 Severe hypoalbuminemia (<2.5) 18 Anemia 12 14 23 GERD 32 5 3 Internal hernia 6 Dumping 8 28 Mortality 7 1 Excess weight loss < 50% 45 19 Weight regain 48 25

Complications

slide-30
SLIDE 30

Comorbidity Resolution

Cases LSG RYGB OAGB Total number with T2DM 23 33 62 Number with remission 13 25 59 Percentage 56.5 75.8 95.1 Total number with HTN 30 47 48 Number with remission 14 34 41 Percentage 46.7 72.3 85.4 Total number with dyslipidemia 21 50 45 Number with remission 11 37 42 Percentage 52.4 74.0 93.3

slide-31
SLIDE 31

Takeaways

  • “OAGB is the effective and safe procedure for patients

who are compliant in taking their supplements.”

  • “LSG may be done in non-compliant patients and those

ready to accept weight regain.”

slide-32
SLIDE 32
  • Complete F/U in 126 of 175 (72%)
  • Gastric tube over 32 Fr bougie
  • Gastrojejunostomy 200 cm from ligament of

Treitz

  • PPIs for 6 months
slide-33
SLIDE 33

Early Complications

  • Reoperations in 6 (4.8%)

Early mortality (< 3 months) Early complications (< 3 months) 10 (7.9%) Major complications 7 (5.5%) Peri-anastomotic abscess 1 (0.8%) Peritonitis due to a traumatic injury of the afferent loop 1 (0.8%) Intra-abdominal bleeding 1 (0.8%) Port site herniation 3 (2.4%) Anastomotic stricture 1 (0.8%) Minor complications 3 (2.4%) Marginal ulcer 1 (0.8%) Deep vein thrombosis 1 (0.8%) Minor wound infection 1 (0.8%)

slide-34
SLIDE 34

Late Complications

  • Reoperation in 6 (4.8%)
  • Marginal ulcer in 5 (4%)
  • Iron deficiency anemia in 4 (3.2%)
slide-35
SLIDE 35

Outcomes

  • %Excess BMI Loss: 71.5% ± 26.5
  • Avg BMI 47 → 31 at 5 yr
  • Weight regain in 4 (3.2%)
  • Pouch revision in 3
  • Severe malnutrition in 2 (1.6%)
  • Revision operation being considered
slide-36
SLIDE 36

Outcomes

  • Complete T2DM remission in 82%

Before OAGB (n = 126) 60 months after OAGB (n = 126) P Hypertension 48 (38%) 23 (18.5%) < 0.001 Hyperlipidemia 31 (25%) 6 (5%) < 0.001 Joint pain 52 (41%) 33 (26.5%) 0.014 Type 2 diabetes 28 (22%) 5 (4%) < 0.001 Sleep apnea 24 (19.5%) 12 (9.5%) 0.029

slide-37
SLIDE 37
  • 31 published articles prior to December

2014

  • 16 single-arm case studies
  • 15 comparison studies
  • LAGB vs OAGB (8)
  • LSG vs OAGB (6)
  • RYGB vs OAGB (5)
slide-38
SLIDE 38

Outcomes

  • Operative time ≈ 50 to 90 min
  • Early complications (1 – 2%)
  • Bleeding, leak, wound infection
  • Late complications (2 – 8%)
  • Bile reflux, marginal ulcer, iron deficiency
  • Low mortality rate (< 1%)
slide-39
SLIDE 39
slide-40
SLIDE 40

Versus LAGB

Remission of T2DM Post-op BMI

slide-41
SLIDE 41

Versus LSG

1-Year %EWL Remission of T2DM

slide-42
SLIDE 42

Versus LSG

Revision Surgery Rate

slide-43
SLIDE 43

Revision Surgery Rate

Versus RYGB

Operative Time 1-Year %EWL

slide-44
SLIDE 44

Versus RYGB

Remission of T2DM

slide-45
SLIDE 45

Role of OAGB

slide-46
SLIDE 46

Bariatric Surgery Algorithm

  • Patient
  • Binge

eating

  • GERD –
  • DS
  • GERD +
  • BPD
  • Not binge

eating

  • T2 DM

+

  • GERD –
  • OAGB
  • GERD +
  • T2 DM –
  • GERD +
  • RYGB
  • GERD –
  • Sleeve

Himpens, Surg Endo, 2015

slide-47
SLIDE 47

One Anastomosis Gastric Bypass

  • Surge of international interest
  • May offer advantages over

VSG and RYGB in select patients

  • Merits further investigation, ideally with

randomized controlled trials

slide-48
SLIDE 48

Thank You